72 related articles for article (PubMed ID: 3490906)
1. Detection of activated Mr 21,000 protein, the product of ras oncogenes, using antibodies with specificity for amino acid 12.
Wong G; Arnheim N; Clark R; McCabe P; Innis M; Aldwin L; Nitecki D; McCormick F
Cancer Res; 1986 Dec; 46(12 Pt 1):6029-33. PubMed ID: 3490906
[TBL] [Abstract][Full Text] [Related]
2. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse.
Pullano TG; Sinn E; Carney WP
Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786
[TBL] [Abstract][Full Text] [Related]
3. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
[TBL] [Abstract][Full Text] [Related]
4. A monoclonal antibody reactive with an activated ras protein expressing valine at position 12.
Carney WP; Hamer P; Petit D; Wolfe H; Cooper G; Lefebvre M; Rabin H
J Cell Biochem; 1986; 32(3):207-14. PubMed ID: 3536974
[TBL] [Abstract][Full Text] [Related]
5. Antibody to ras proteins in patients with colon cancer.
Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K
Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896
[TBL] [Abstract][Full Text] [Related]
6. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
7. Generation of monoclonal antibodies specific for ras p21 Glu-12 oncoproteins: detection in carcinogen-induced mammary carcinomas.
Garlick DS; Sukumar S; Barbacid M; Petit D; Hamer PJ; Leav I; Lavecchio JA; Trimpe KL; Carney WP
Hybridoma; 1991 Feb; 10(1):95-102. PubMed ID: 2032737
[TBL] [Abstract][Full Text] [Related]
8. Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.
Triozzi PL; Stoner GD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):185-92. PubMed ID: 9346851
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
10. Anti-peptide antibodies to oncoproteins: the predetermined specificity and detection of gene products predicted by nucleotide sequence analyses.
Tanaka T; Cline MJ
Adv Biotechnol Processes; 1988; 10():61-80. PubMed ID: 3058147
[No Abstract] [Full Text] [Related]
11. Genetic studies of the lac repressor. XIV. Analysis of 4000 altered Escherichia coli lac repressors reveals essential and non-essential residues, as well as "spacers" which do not require a specific sequence.
Markiewicz P; Kleina LG; Cruz C; Ehret S; Miller JH
J Mol Biol; 1994 Jul; 240(5):421-33. PubMed ID: 8046748
[TBL] [Abstract][Full Text] [Related]
12. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
13. Presence and possible role of c-ras and nuclear (c-fos and c-jun) proto-oncogene products in preimplantation embryonic development in mice.
Ahmad K; Naz RK
Mol Reprod Dev; 1993 Nov; 36(3):297-306. PubMed ID: 8286110
[TBL] [Abstract][Full Text] [Related]
14. Establishment of four mouse hybridoma cell lines producing monoclonal antibodies reactive with ras oncogene product p21.
Kuzumaki N; Oda A; Yamagiwa S; Taniguchi N; Kobayashi H; Oikawa T
J Natl Cancer Inst; 1986 Dec; 77(6):1273-9. PubMed ID: 3540418
[TBL] [Abstract][Full Text] [Related]
15. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Schott ME; Wells DT; Schlom J; Abrams SI
Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
[TBL] [Abstract][Full Text] [Related]
16. Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding.
Clark R; Wong G; Arnheim N; Nitecki D; McCormick F
Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5280-4. PubMed ID: 3927300
[TBL] [Abstract][Full Text] [Related]
17. Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers.
Yoshida K; Hamatani K; Koide H; Ikeda H; Nakamura N; Akiyama M; Tsuchiyama H; Nakayama E; Shiku H
Cancer Res; 1988 Oct; 48(19):5503-9. PubMed ID: 3046740
[TBL] [Abstract][Full Text] [Related]
18. Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products.
Caruso A; Schlom J; Vilasi V; Weeks MO; Hand PH
Int J Cancer; 1986 Oct; 38(4):587-95. PubMed ID: 3489681
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA
Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715
[TBL] [Abstract][Full Text] [Related]
20. Mutations in ras oncogenes: rare events in ultraviolet B radiation-induced mouse skin tumorigenesis.
Khan SG; Mohan RR; Katiyar SK; Wood GS; Bickers DR; Mukhtar H; Agarwal R
Mol Carcinog; 1996 Feb; 15(2):96-103. PubMed ID: 8599584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
